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Introduction {#sec005}
============

Latest data shows an estimated 35·3 million people lived with HIV, of which 9·7 million people in low-income and middle-income countries were receiving antiretroviral therapy (ART) in 2012. Breakthroughs in the "treatment as prevention" strategy, e.g. using ART in pregnant women, people with HIV or with pre-exposure prophylaxis, have resulted in significant reduction in HIV transmission rate, and thus are very important for public health\[[@pone.0146659.ref001]\]. HIV ART with adequate adherence is conventionally the most effective prevention strategy, known as "treatment as prevention", due to its significant association with a reduced HIV transmission rate. Furthermore, ART can help HIV-infected patients restore immune function, prolonging life and improving the quality of life\[[@pone.0146659.ref002]\]. Adequate adherence to ART plays an important role in sustaining viral suppression, preventing the development of disease and decreasing the mortality rate. Drug resistance quickly occurs during the therapeutic process due to poor adherence, which may reduce treatment efficacy, promote disease progression, and increase the risk of transmission \[[@pone.0146659.ref003]\]. However, many HIV-infected individuals do not achieve or maintain high levels of adherence. Globally, nearly 40% of HIV-infected patients did not maintain an adherence rate higher than 90% in 2011\[[@pone.0146659.ref004]\].

China is the most HIV-affected region in Asia. HIV epidemics in China tend to be concentrated among members of groups at high risk of acquiring or spreading HIV\[[@pone.0146659.ref005]\]. However, no systematic review of the ART adherence in China has been performed. Further, access to antiretroviral therapy and adherence in different populations may vary, and no systematic review of comparisons and variations in ART adherence between different populations has been performed.

We performed this meta-analysis to provide a pooled proportion of HIV-infected patients with adequate ART adherence in different high-risk populations to prevent the spread of HIV/AIDS in China. We also provide comparisons of ART adherence between these important populations.

Methods {#sec006}
=======

Search Strategy and Selection Criteria {#sec007}
--------------------------------------

We searched PubMed, Chinese Biomedical Literature Database (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang (Chinese) to identify any study in each database published from January 1985 to May 2015. The following detail search strategy was used in PubMed: (HIV or "human immune\*" or "acquired immunodeficiency syndrome") and ("China" or "Chinese") and ("adherence" or "compliance" or "pill counts") and ("ART" OR ''HAART" OR ''antiretroviral\*"). The same search strategies were used for each database. No language restriction was placed on the search process. In addition, we also screened the references of the retrieved paper. If the eligible papers were not obtained, we would contact the corresponding author of the paper for detailed information via e-mail.

Only descriptive epidemiological studies that reported ART adherence in HIV-positive specific groups, such as pregnant women, children, former commercial and plasma donors (FCPD), injection drug users (IDUs), men who have sex with men (MSM), heterosexual transmission group (HTG), were eligible. We excluded qualitative studies, literature reviews, case studies, cost-effectiveness studies, meetings, discussions, editorials, research overviews, book reviews, letters, and news articles. We excluded studies that did not provide useable data, had fewer than 30 participants and were conducted in countries outside China.

Study Selection and Data Extraction {#sec008}
-----------------------------------

Two authors (ZH and WFZ) independently screened the titles and abstracts of all of the identified studies. For each study, one reviewer (LL) extracted the data and a second reviewer (ZM) checked the accuracy. Disagreements would be discussed and resolved by a third investigator (CXZ) if these two investigators could not reach a consensus. For the 36 studies included here, there were no disagreements between the first reviewer (LL) and the second reviewer (ZM). [Fig 1](#pone.0146659.g001){ref-type="fig"} shows the flowchart for selecting articles \[[@pone.0146659.ref006]--[@pone.0146659.ref041]\].

![PRISMA 2009 flow diagram literature search and study selection.\
PRISMA diagram showing the different steps of systematic review, starting from literature search to study selection and exclusion.](pone.0146659.g001){#pone.0146659.g001}

We developed a data abstraction form and extracted the following data from the eligible studies: studies characteristics (authors, years, design, and study regions), study population (age, sex, and sample size), ART regimen, adherence threshold (e.g., 90%, 95%, 100%), methods of outcomes measurement, and adherence assessor. The population was divided into pregnant women, children, FCPD, IDUs, FSP of HIV-positive individuals, MSM, and TB/HIV co-infected people. We also obtained data from the website of the Chinese administrative region; these data were used to categorize regions (eastern China, south-central China, north China, northwest China, southwestern China, and northeast China) and the gross domestic product in \$US per individual in 2013 (low income (\<\$5520), low-middle income (\$5635--6750), high-middle income (\$6892--9961), and high income (\>\$10,915)\[[@pone.0146659.ref042],[@pone.0146659.ref043]\].

Quality Assessment {#sec009}
------------------

We used the Agency of Healthcare Research and Quality (AHRQ) assessment to assess the quality of the eligible literature. The AHRQ is an 11-item questionnaire with three-options for each item, and the total score of the AHRQ is 11. Article quality was assessed as low (from 0 to 3), moderate (from 4 to 7), or high (from 8 to 11)\[[@pone.0146659.ref044]\].

Statistical Analysis {#sec010}
--------------------

Adequate adherence was defined as the proportion of people who reported≥90% adherence to ART, which was referred in each study as the effect size index (ES). Random-effects meta-analysis was used to calculate weighted mean estimates across studies and 95% CIs, because random-effects models are more conservative and provide better estimates with wider confidence\[[@pone.0146659.ref045]\]. Data were pooled with proportions transformed prior to pooling using the Freeman--Tukey double arcsine transformation and then back transformed to the original scale\[[@pone.0146659.ref046]\]. We calculated the I^2^ (and its 95% confidence intervals) and tau^2^ to assess between-study heterogeneity, and H^2^ (and its 95% confidence intervals) to assess within-study heterogeneity \[[@pone.0146659.ref047],[@pone.0146659.ref048]\].

Subgroup analyses and meta-regression analyses were used to explore potential heterogeneity in the following categories: study regions (eastern China, south China, south-central China, north China, northwest China, southwestern China, and northeast China), publication year, study design (observational or interventional study), adherence threshold (90--99% and 100%),), measure of adherence (single self-reported, combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process)), sample size (≤100 and \>100), and study quality score (\<8 and ≥8). The subgroup analyses in MSM, FCPD, and HTG of HIV-infected patients were not performed because that the number of studies (n≤2) in these subgroup were too small.

To establish the robustness of the outcome by sensitivity analyses, we applied a fixed effects model, excluded studies with a low number of participants\[[@pone.0146659.ref049]\], and excluded studies with a low quality score\[[@pone.0146659.ref019]\]. A funnel plot was used to explore publication bias. Funnel-plot asymmetry was further assessed by a Begg's test and Egger's linear regression test\[[@pone.0146659.ref050]\]. We performed all analyses using Stata software (version 13.0) and R software (version 2-15-2).

Results {#sec011}
=======

Characteristics of Included Studies {#sec012}
-----------------------------------

We identified 4365 papers from database searches and 92 papers through Internet, hand, and reference list searches. During the abstract screening, 3955 papers were excluded, leaving 502 full-text papers to be assessed for eligibility. Finally, we included 36 papers in this meta-analysis ([Fig 1](#pone.0146659.g001){ref-type="fig"}).

[Table 1](#pone.0146659.t001){ref-type="table"} notes the characteristics of the 36 eligible studies. Most studies were conducted in south-central China (n = 17, 47.22%), followed by south-western China (n = 8, 22.22%), northwest China (n = 4, 11.11%), and trans-regional cities (n = 4, 11.11%). Adherence was most commonly reported in studies of pregnant women (n = 14, 38.89%), followed by IDU (n = 9, 25%), children (n = 4, 11.11%) and elderly patients (n = 3, 8.33%). Most studies (n = 28, 77.78%) were observational, and 8 (22.22%) were interventional studies. 10 (27.78%) studies used a self-reported adherence rate, whereas 26 (72.22%) used combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process.

10.1371/journal.pone.0146659.t001

###### Characteristics of Studies Included in the Meta-Analysis.

Note: & Quality score assessed by Agency of Healthcare Research and Quality (AHRQ); \$ Income level is divided to high income (\>10915), high-middle income (6892--9961), low-middle income, low income (\<5520) according to GDP (in \$US per head); FCPD = former commercial and plasma donors; IDU = injection drug users; MSM = men who have sex with men; HTG = heterosexual transmission group; OBS = observational study; INT = interventional study; cART = combined antiretroviral therapy; sdNVP = single-dose nevirapine; AZT = zidovudine; D4T = stavudine; DDI = dideoxyinosine; NVP = nevirapine; EFV = efavirenz; 3TC = Lamivudine; LPV/r = Lopinavir/ritonavir; TDF = tenofovir disoproxil fumarate.
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  Study(years)           study years   No of participants     Study design   Region                Income level^\$^     cART regimens                                                  Adherence Assessor                  Adherence (%);Threshold for Measurement                                          Scores of study quality^&^
  ---------------------- ------------- ---------------------- -------------- --------------------- -------------------- -------------------------------------------------------------- ----------------------------------- -------------------------------------------------------------------------------- ----------------------------
  Wang YZ (2008)         2005--2006    122 pregnant women     OBS            Southwestern China    Low income           AZT+NVP; sdNVP                                                 Patient or physician                100%; doses taken from 28 weeks of gestation                                     8
  Wang YZ (2008)         2005--2007    158 pregnant women     OBS            Southwestern China    Low income           D4T+3TC+NVP/EFV;AZT+NVP; sdNVP                                 Patient or physician                100%; doses taken from 28 weeks of gestation                                     8
  Pang J(2009)           2005--2008    110 pregnant women     OBS            South-central China   Low income           Three drugs or two drugs                                       Clinic staff                        100%; doses taken from 28 weeks of gestation                                     5
  Wang YZ (2008)         2005--2007    167 pregnant women     OBS            Southwestern China    Low income           D4T+3TC+NVP/EFV;AZT+NVP; sdNVP                                 Medical record                      100%; doses taken from 28 weeks of gestation                                     8
  Wang LH(2009)          2004--2008    312 pregnant women     OBS            Trans-regional        Low income           standard therapeutic regimen for pregnant women                Clinic staff                        100%; doses taken from 28 weeks of gestation                                     7
  Wang Q(2011)           2005--2006    1490 pregnant women    OBS            Trans-regional        Low income           D4T+3TC+NVP/EFV;AZT+NVP; sdNVP                                 Patient or physician                100%; doses taken from antenatal to postpartum                                   8
  Gui XZ(2012)           2006--2010    208 pregnant women     OBS            South-central China   Low income           AZT+3TC+NVP/EFV                                                Self-reported                       100%; doses taken from antenatal to postpartum                                   6
  Hu HM(2012)            2010--2011    678 pregnant women     INT            Southwestern China    Low income           AZT+3TC+LPV/r;AZT+3TC+EFV/NVP                                  Patient or physician                100%; doses taken from antenatal to postpartum                                   8
  Li AJ (2012)           2006--2008    158 pregnant women     OBS            Southwestern China    Low income           AZT+3TC+NVP/EFV; AZT+NVP; sdNVP                                Medical record                      95%; based on past 1 month                                                       6
  Chen SP(2013)          2012          30 pregnant women      INT            South-central China   High-middle income   No report                                                      Self-reported                       95; doses taken in past 1 months                                                 5
  AILIKA.Shawuli(2013)   2010--2012    1303 pregnant women    OBS            Northwest China       Low-middle income    AZT; 3TC+NVP; sdNVP; AZT+3TC; AZT+3TC+LPV/r; AZT+3TC+EFV/NVP   Patient and physician               100%; doses taken from antenatal to postpartum                                   6
  Wang Q(2013)           2005--2008    1414 pregnant women    OBS            Trans-regional        Low income           Standard therapeutic regimen for pregnant women and newborn    Medical record and patient report   100%; doses taken from antenatal to postpartum                                   8
  Wu HP(2013)            2009--2011    314 pregnant women     OBS            Southwestern China    Low income           Standard therapeutic regimen for pregnant women                Patient and physician               100%; doses taken from antenatal to postpartum                                   7
  Li ZJ(2014)            2005--2013    69 pregnant women      OBS            Southwestern China    Low income           AZT+3TC+LPV/r                                                  Patient and physician               100%; doses taken from antenatal to postpartum                                   4
  Yu RH(2007)            2006          72 FCPD                OBS            Eastern China         Low income           D4T+3TC+NVP/ATV;D4T+DDI+NVP;3TC+DDI+EFV                        Self-reported                       95%; No. of pills taken/pills prescribed in past four days                       8
  Yuan Y(2012)           2003--2009    606 FCPD               OBS            South-central China   Low income           AZT/D4T+DDI+NVP/EFV;AZT/D4T+3TC+NVP/EFV                        Patient or physician                90%; doses taken in past 1 month                                                 6
  Lu J(2008)             2006          62 IDUs                OBS            Northwest China       Low-middle income    D4T+3TC+NVP/EFV;AZT+3TC+NVP                                    Self-reported                       95%; based on past 1 week                                                        8
  Wang HH(2008)          2007          111 IDUs               OBS            South-central China   Low income           AZT+3TC+NVP/EFV;                                               Self-reported                       90%; No. of the doses taken/No. of doses prescribed in past 1 month              7
  Zhou J (2008)          2007--2008    116 IDUs               INT            South-central China   Low-middle income    AZT+3TC+NVP/EFV;                                               Clinic staff and pill count         \>95%; No. of pills taken/No. of pills prescribed over prior 1 month             9
  Lu J(2008)             2007--2008    180 IDUs               OBS            Trans-regional        Low-middle income    D4T+3TC+NVP/EFV;AZT+3TC+NVP/EFV                                Self-reported                       95%; No. of doses recorded/total No. of doses prescribed in the past 1 week      9
  Yang CB(2010)          2007--2009    102 IDUs               OBS            Southwestern China    Low income           D4T+3TC+NVP;AZT+3TC+NVP/EFV                                    Patient or physician                100%; based on past 12 months                                                    6
  Su FQ(2011)            2007          60 IDUs                INT            South-central China   Low income           No report                                                      Self-reported                       100%; doses taken in past 1 month                                                4
  Lu J(2013)             2012          180 IDUs               OBS            Northwest China       Low-middle income    No report                                                      Pill count                          95%; No. of pills taken/No. of pills prescribed                                  7
  Qin YL(2013)           2009--2011    73 IDUs                INT            South-central China   High-middle income   AZT+3TC+NVP/EFV; D4T+3TC+NVP/EFV;                              Self-reported                       100%; doses taken/ doses prescribed in the past 1 week                           6
  Ye HL(2013)            2010          60 IDUs                OBS            South-central China   Low income           AZT+3TC+NVP/EFV/LPV/r; D4T+3TC+NVP/EFV;TDF+3TC+LPV/r           Clinic staff                        100%; doses taken in past 6 months                                               6
  Deng MH(2012)          2010          72 elderly patients    INT            South-central China   Low income           No report                                                      Patient or physician                100; doses taken in past 1 month                                                 5
  Liu JR(2013)           2012          63 elderly patients    OBS            South-central China   Low income           No report                                                      Patient and physician               100%; doses taken in past 3 months                                               4
  Lu MR(2014)            2013          100 elderly patients   INT            South-central China   Low income           No report                                                      Clinic staff and pill count         100%; doses taken/ doses prescribed in the past 6 months                         4
  Zhou YF(2012)          2009--2012    200 MSM                INT            South-central China   Low-middle income    No report                                                      Self-reported                       100%; doses taken                                                                8
  Qiao JK(2014)          2010--013     200 MSM                OBS            Northern China        Low income           AZT/D4T+3TC+NVP/EFV                                            Clinic staff and pill count         95%; No. of pills taken/No. of pills prescribed                                  7
  Liu AW(2007)           No report     40 children            OBS            Eastern China         Low income           D4T+3TC+NVP/EFV;AZT+3TC+NVP/EFV;                               Clinic staff                        100%; based on past 1 month                                                      6
  Chang YL(2009)         2007--2009    46 children            OBS            Northwest China       Low-middle income    D4T+3TC+NVP/EFV;AZT+3TC+NVP/EFV                                Patient or physician                100%; based on past 3 months                                                     5
  Liu X (2011)           2009          87 children            OBS            South-central China   Low income           AZT/D4T+3TC+EFV;AZT/D4T+3TC+LPV/r;ABC+3TC+LPV/r                Plasma drug monitoring              100%; plasma concentration of drugs higher than 1000ng/ml in the past 3 visits   8
  Wei XB(2012)           2005--2011    49 children            OBS            South-central China   Low income           Standard therapeutic regimen for children                      Pill count and self-reported        100%; No. of pills taken/No. of pills prescribed                                 4
  Dong XB(2014)          No report     93 HTG                 OBS            South-central China   Low-middle income    No report                                                      Medical record                      100%; No. of pills taken/No. of pills prescribed                                 4
  Lee SS (2007)          No report     50 HTG                 OBS            South-central China   High income          No report                                                      self-reported                       100%; No. of pills taken/No. of pills prescribed                                 7

[Table 1](#pone.0146659.t001){ref-type="table"} presents the study quality score assessed using the AHRQ; 12 (33.33%) were scored as high quality, and 24 (66.67%) were scored as moderate quality.

Overall Adherence to Antiretroviral Therapy {#sec013}
-------------------------------------------

Thirty-six studies, which included 6885 HIV-positive individuals, reported ART adherence ([Fig 2](#pone.0146659.g002){ref-type="fig"}). Approximately 77.61% (95% CI = 71.63--83.08) of HIV patients had a high level of adherence; however, high levels of heterogeneity were observed between studies (I^2^ = 96.6%, 95%CI = 96%-97.2%;tau^2^ = 0.1597;H = 5.44, 95%CI = 4.98--5.95).

![Meta-analyses of adequate adherence to antiretroviral therapy in special population groups in china.\
Adequate adherence was defined as the proportion of people who reported≥90% adherence to ART, which was estimated in each study as the effect size index (ES).](pone.0146659.g002){#pone.0146659.g002}

ART Adherence Rate by Different Subgroups {#sec014}
-----------------------------------------

The ART adequate adherence rate varied widely between different high-risk populations ([Fig 2](#pone.0146659.g002){ref-type="fig"}). Three studies, which included 149 old HIV-infected patients, reported the highest ART adequate adherence rate (89.39%, 95% CI = 72.01--99.26) with high heterogeneity between the studies (I^2^ = 86.2%, 95%CI = 60--95.2%; tau^2^ = 0.128). While, only two studies, which included 143 heterosexual transmission patients, reported the lowest ART adequate adherence rate (51.55%, 95% CI = 41.33--61.71) with low heterogeneity between the studies (I^2^ = 31.3%, tau^2^ = 0.007).

A total of 14 studies reported ART adequate adherence rate in the subgroup of pregnant women, and the rate was 83.48% (95% CI = 74.72--94.91); however, high heterogeneity was observed between the studies (I^2^ = 98.20%, 95%CI = 97.7--98.6; tau^2^ = 0.168). The subgroup analyses in pregnant women were also performed, and we found that the adequate adherence rate in pregnant women continually increased from 79.18% (95% CI = 63.80--92.2) in 2008 to 95.65% (95% CI = 89.27--99.45) in 2014 ([Table 2](#pone.0146659.t002){ref-type="table"}). The region with the highest adherence rate in pregnant women was south-central China (96.05%, 95% CI = 83.13--100), followed by south-western China (85.68%, 95% CI = 74.18--93.93) and northwest China (66.23%, 95% CI = 62.27--69.13). The studies with small sample size reported higher adherence rate (95.89%, 95% CI = 87.93--99.94%) than that in studies with large sample size (77.45%, 95% CI = 66.06--87.09%) in pregnant women ([Table 2](#pone.0146659.t002){ref-type="table"}).

10.1371/journal.pone.0146659.t002

###### Subgroup Analyses of Adherence (95%CI) to Antiretroviral Therapy in Special Population Groups in China.^&^

Note: & = Number of studies (k≤2) too small to test for small study effects. \$ = combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process.
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  Subgroup               No. of studies                   Proportion, 95%CI(100%)   Heterogeneity                                                          
  ---------------------- -------------------------------- ------------------------- ------------------------ --------------------- ----------------------- -------
  Pregnant women         Publication year                                                                                                                  
                         2008                             3                         79.18(63.80 to 91.00)    90.7(75.5 to 96.4)    3.27 (2.02 to 5.3)      0.081
                         2009                             2                         68.60 (27.10 to 100)     99.5                  14.17                   1.664
                         2011                             1                         85.01(82.96 to 86.95)    \-                    \-                      \-
                         2012                             3                         84.43(65.34 to 96.84)    96.2(92 to 98.2)      5.14(3.53 to 7.48)      0.148
                         2013                             4                         88.11(74.41 to 97.15)    98.4(97.4 to 99)      7.84(6.18 to 9.94)      0.12
                         2014                             1                         95.65(89.27 to 99.45)    \-                    \-                      \-
                         Regions                                                                                                                           
                         Northwest China                  1                         66.23 (63.27 to 69.13)   \-                    \-                      \-
                         South-central China              3                         96.05(83.13 to 100)      99.5 (99.3 to 99.7)   14.6 (12.06 to 17.68)   0.274
                         Southwestern China               7                         85.68(74.81 to 93.93)    94.9 (91.8 to 96.9)   4.44 (3.49 to 5.66)     0.126
                         Trans-reginoal                   3                         66.77(37.46 to 90.32)    90.7 (75.6 to 96.5)   3.28(2.02 to 5.31)      0.125
                         Sample size                                                                                                                       
                         ≤100                             4                         95.89(87.93 to 99.94)    78.9(43.6 to 92.1)    2.18(1.33 to 3.56)      0.065
                         \>100                            10                        77.45(66.06 to 87.09)    98.6 (98.2 to 98.9)   8.49(7.45 to 9.69)      0.163
                         Adherence measure                                                                                                                 
                         Single self-reported             2                         94.40(72.45 to 100)      90.1                  3.18                    0.171
                         Combined methods^\$^             12                        81.42(71.16 to 89.88)    98.4(98 to 98.8)      7.97(7.04 to 9.02)      0.174
                         Quality score of study quality                                                                                                    
                         \<8                              8                         82.86(64.92 to 95.38)    98.7(98.2 to 99)      8.71(7.52 to 10.08)     0.338
                         ≥8                               6                         84.74(79.13 to 89.62     91.2 (83.7 to 95.3)   3.38 (2.48 to 4.61)     0.027
  Injection drug users   Publication year                                                                                                                  
                         2008                             4                         67.47(55.36 to 78.52)    84.4(60.9 to 93.8)    2.53(1.6 to 4)          0.053
                         2010                             1                         46.08(36.47 to 55.84)    \-                    \-                      \-
                         2011                             1                         70(57.72 to 81.02)       \-                    \-                      \-
                         2013                             3                         59.34(53.17 to 65.36)    0(0 to 89.5)          1(1 to 3.09)            0
                         Regions                                                                                                                           
                         Northwest China                  2                         71.61(44.38 to 92.40)    92.4                  3.62                    0.147
                         South-central China              5                         64.05(57.24 to 70.60)    50.5(0 to 81.8)       1.42(1 2.35)            0.012
                         Southwestern China               1                         46.08(36.47 to 55.84)    \-                    \-                      \-
                         Trans-reginoal                   1                         56.91(48.04 to 65.56)    \-                    \-                      \-
                         Sample size                                                                                                                       
                         ≤100                             4                         69.23(56.37 TO 80.77)    78.3(41.4 to 91.9)    2.14 (1.31 to 3.52)     0.056
                         \>100                            5                         58.22(50.49 to 65.75)    71.7(28.7 to 88.8)    1.88(1.18 to 2.99)      0.022
                         Adherence threshold                                                                                                               
                         90--99%                          4                         67.59(55.65 to 78.49)    84.1(60 to 93.7)      2.51(1.58 to 3.98)      0.052
                         100%                             5                         58.56(50.20 to 66.70)    65.2(9 to 86.7)       1.7(1.05 to 2.74)       0.023
                         Adherence measure                                                                                                                 
                         Single self-reported             5                         67.54(56.98 to 77.28)    80.2(53.3 to 91.6)    2.24(1.46 to 3.44)      0.048
                         Combined methods^\$^             4                         56.75(49.01 to 64.33)    58.1 (0 to 86.1)      1.55(1 to 2.68)         0.014
                         Quality score of study quality                                                                                                    
                         \<8                              3                         66.36 (49.73 to 81.17)   72.9(37.8 to 88.2)    1.92(1.27 to 2.91)      0.031
                         ≥8                               6                         61.09(52.78 to 69.10)    88.2(67.1 to 95.8)    2.91(1.74 to 4.86)      0.077
  Children               Publication year                                                                                                                  
                         2007                             1                         93.94(82.59 to 99.89)    \-                    \-                      \-
                         2009                             1                         97.83(90.90 to 1)        \-                    \-                      \-
                         2011                             1                         80.46(71.4 to 88.19)     \-                    \-                      \-
                         2012                             1                         81.63(69.41 to 91.40)    \-                    \-                      \-
                         Regions                                                                                                                           
                         Eastern China                    1                         93.94(82.59 to 99.89)    \-                    \-                      \-
                         Northwest China                  1                         97.83(90.90 to 1)        \-                    \-                      \-
                         South-central China              2                         80.92(73.77 to 87.20)    75.9(33.6 to 91.2)    2.04(1.23 to 3.38)      0.061
                         Quality score of study quality                                                                                                    
                         \<8                              3                         92.11(80.28 to 99.15)    72.9(9 to 92)         1.92(1.05 tp 3.53)      0.063
                         ≥8                               1                         80.46(71.40 to 88.19)    \-                    \-                      \-
  Elderly patients       Publication year                                                                                                                  
                         2012                             1                         69.44(53.28 to 83.58)    \-                    \-                      \-
                         2013                             1                         95.24(88.28 to 99.39)    \-                    \-                      \-
                         2014                             1                         96(88.32 to 99.93)       \-                    \-                      \-

A subgroup analysis of ART adherence rate in IDUs was also performed ([Table 2](#pone.0146659.t002){ref-type="table"}). In IDUs, two studies reported the highest adherence rate in northwest China (71.61%, 95% CI: 44.38--92.40) with high heterogeneity between the studies (I^2^ = 92.4%, tau^2^ = 0.147); while only one studies reported the adherence rate in southwest China, which reported the lowest adherence rate (46.08%, 95% CI: 36.47--55.84).

Analyses of ART adherence rate in elderly and pediatric patient subgroups were also performed. However, no significant variations were observed between the subgroups in publication year, regions, and study quality ([Table 2](#pone.0146659.t002){ref-type="table"}). Moreover, the subgroup analyses in MSM, FCPD, and HTG were not performed because only two studies were available for these specific groups.

Meta-Regression Analyses {#sec015}
------------------------

The meta-regression for ART adherence is shown in [Table 3](#pone.0146659.t003){ref-type="table"}. In the univariate meta-regression model, high-risk populations, sample size, and study quality score were associated with ART adherence rate. In the multivariable model, high-risk populations was the main factors explaining heterogeneity (variance explained 28.14%). Sample size and study quality score did not retain significance.

10.1371/journal.pone.0146659.t003

###### Results of Meta-regression for Adherence to Antiretroviral Therapy in China.

Note: \$, combined method of two or more single measure methods including self-reported, pill count, checking medical records, and clinic staff monitoring in the whole study process. OBS = observational study; INT = interventional study;
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  Covariate                                                        No. of studies   Univariate analyses       Multivariable analyses                                          
  ---------------------------------------------------------------- ---------------- ------------------------- ------------------------ ------- ---------------------- ------- -------
  Population (HTG is reference)                                                                               0.028                    24.46                          0.032   28.14
      Former commercial and plasma donors                          2                0.09(-0.26 to 0.43)       0.618                            0.11(-0.26 to 0.48)    0.551   
      Injection drug users                                         9                0.10(-0.17 to 0.38)       0.439                            0.13(-0.16 to 0.41)    0.367   
      Pregnant women                                               14               0.29(0.02 to 0.55)        0.034                            0.30(0.03 to 0.72)     0.029   
      Men who have sex with men                                    2                0.33(-0.01 to 0.67)       0.06                             0.36(0.01 to 0.72)     0.047   
      Children                                                     4                0.36(0.06 to 0.66)        0.019                            0.36(0.02 to 0.71)     0.038   
      Elderly patients                                             3                0.35(0.04 to 0.67)        0.03                             0.32(0.01 to 0.67)     0.041   
  Regions (trans-regional is reference)                                                                       0.791                    -8.13                                  
      Eastern China                                                2                0.06(-0.29 to 0.41)       0.722                                                           
      Northwest China                                              4                0.13(-0.15 to .41)        0.466                                                           
      South-central China                                          17               0.14(-0.08/ to 0.36)      0.206                                                           
      Southwestern China                                           8                0.17(-0.08 to 0.41)       0.173                                                           
      Northern China                                               1                0.17(-0.28 to 0.62)       0.447                                                           
  Study design (INT vs reference)                                  36               0.06(-0.10 to 0.21)       0.464                    -1.11                                  
  Income level                                                     36               -0.05(-0.15 to 0.06)      0.371                    -0.78                                  
  Sample size (≤100 vs \>100)                                      36               -0.14(-0.25 to -0.02)     0.027                    10.77   0.01(-0.20 to 0.21)    0.958   
  Quality score of study quality                                   36               -0.03(-0.07 to 0.00002)   0.050                    7.8     -0.02(-0.07 to 0.02)   0.328   
  Year of publication                                              36               0.02(-0.001 to 0.05)      0.064                    6.68                                   
  Adherence Assessor(single self-reported vs combined methods\$)   36               0.05(-0.03 to 0.17)       0.197                    2.35                                   
  Threshold for Measurement (%)                                    36               0.04(-0.05 to 0.12)       0.355                    -0.17                                  

Sensitivity Analyses {#sec016}
--------------------

We performed sensitivity analyses of the ART adherence rate by applying a fixed effects model, and we found similar adherence rate between random-effect mode and fixed-effect mode in the overall analysis and the subgroup analyses ([Fig 2](#pone.0146659.g002){ref-type="fig"}). Moreover, excluded studies with a low number of participants, and excluded studies with a low quality score both produced similar adherence rate.

Evaluation of Publication Bias {#sec017}
------------------------------

We produced funnel plots and visually examined these plots for signs of asymmetry. We generated funnel plots to assess publication bias of the ART adherence rate. For overall ART adherence rate, the asymmetry observed in the funnel plots was minimal ([Fig 3](#pone.0146659.g003){ref-type="fig"}). We also assessed funnel plot asymmetry using the Egger's linear regression test. No publication bias was observed in the adherence estimate across different specific populations (P\>0.05) ([Table 4](#pone.0146659.t004){ref-type="table"}).

![Funnel plot for adequate adherence to antiretroviral therapy in China.\
Panel A: Funnel Plot before study with \<30 participants was excluded, Freeman-Tukey Double arcsine transformation was used, Egger'S Linear Regression Test (t = -0.282, P = 0.779); Panel B: Funnel Plot after study with \<30 participants was excluded, Egger'S Linear Regression Test (t = -0.365, P = 0.717).](pone.0146659.g003){#pone.0146659.g003}

10.1371/journal.pone.0146659.t004

###### Heterogeneity test and Egger's linear regression test to measure the funnel plot asymmetric.^&^

Note: &, Number of studies (k≤2) too small to test for small study effects

![](pone.0146659.t004){#pone.0146659.t004g}

  Population                            No. of studies   Heterogeneity        Egg\'s test                            
  ------------------------------------- ---------------- -------------------- --------------------- ------- -------- -------
  Pregnant women                        14               98.2(97.7 to 98.6)   7.45 (6.61 to 8.39)   0.168   0.43     0.668
  Men who have sex with men             2                74.4                 1.98                  0.034   -3.14    \-
  Injection drug users                  9                77.8(57.9 to 88.3)   2.12(1.54 to 2.92)    0.038   -0.32    0.962
  Former commercial and plasma donors   2                96.3                 5.21                  0.249   -11.56   \-
  Heterosexual transmission group       2                31.3                 1.21                  0.007   -3.08    \-
  Elderly patients                      3                86.2(60 to 95.2)     2.69(1.58 to 4.58)    0.128   -4.06    0.107
  Children                              4                75.9(33.6 to 91.2)   2.04(1.23 to 3.38)    0.061   -5.01    0.144

Discussion {#sec018}
==========

To our knowledge, this is the first meta-analysis to summarize and compare pooled ART adherence between different high-risk populations in China. We found that approximately 76.6% of HIV-infected individuals at high risk of transmitting HIV have adequate ART adherence. Significant differences in adherence rate were observed between different populations, and the highest ART adherence rate was observed in elderly patients, followed by children, MSM, pregnant women, IDUs, FCPD, and HTG. The adequate ART adherence rate in China was higher than that in India (70%), Spain (50%), and North American countries (57%) and similar to African countries\[[@pone.0146659.ref051]--[@pone.0146659.ref053]\]. Our findings indicated that reaching and maintaining high levels of ART adherence remain major issues in China, especially in some high-risk populations with lower adherence.

The use of ART in decreasing mother-to-child transmission of HIV has played an important role in global HIV/AIDS prevention and control. A recent meta-analysis observed a pooled estimate of 62.0% of pregnant women who had more than 80% ART adherence in high-income countries\[[@pone.0146659.ref054]\]. Our review observed a pooled estimate of nearly 80% of Chinese pregnant women who had 100% ART adherence, which might be due to the Chinese government investing in integrated prevention of mother-to-child transmission (PMTCT). The Chinese government has increased the investment for integrated PMTCT from US\$0.9 million in 2003 to US\$136.8 million in 2010, resulting in a remarkable increase of ART in HIV-infected pregnant\[[@pone.0146659.ref055]\]. In China, PMTCT services were integrated with antenatal and perinatal care, and HIV-infected pregnant women were treated with antiviral drugs when they attended antenatal/perinatal care service. The integration of these health services in terms of HIV prevention may contribute to the maintenance of a high level of ART adherence.

HIV epidemics in China continue to be concentrated among FSWs, IDUs, and MSM, not in the general population; therefore, maintaining high levels of ART adherence in these high-risk populations may be very important for preventing and reducing HIV transmission in China\[[@pone.0146659.ref001]\]. Some previous reviews have observed that 76% of FSWs worldwide and 72% of IDUs in low- and middle-income countries have adequate ART adherence\[[@pone.0146659.ref002],[@pone.0146659.ref056]\]. Our meta-analysis estimated that 62.78% of IDUs had adequate ART adherence in China, which is a very low adherence level compared with that of other low- and middle-income countries. In China, many barriers prevent IDUs from maintaining ART high adherence. For example, poverty can affect adherence by limiting travel to centres for medication, and stigma may also prevent patients from utilizing available free ART services. Several programs, such as needle and syringe exchange programs, have now begun to integrate treatment for opiate addiction into current free ART programs for IDUs in China, which can promote ART adherence. Regarding MSM, no review has assessed ART adherence. Although we observed an encouraging estimate of ART adherence in MSM, this estimate should be interpreted with caution due to the small number of studies. Although exposure among MSM has become the dominant route of HIV transmission, Chinese MSM tend to have very poor access to HIV prevention services, with only a few national prevention programs targeting this population in China\[[@pone.0146659.ref001]\]. A very interesting finding in this meta-analysis was that the lowest ART adequate adherence rate was observed in heterosexual transmission group patients. Considerable sexual transmission continues among MSM and high risk heterosexuals in China, therefore we really have to exert more effort and spend more time on the "treatment as prevention" strategy in these high risk populations.

Our study had some limitations. Firstly, a high heterogeneity was observed between studies. Although we performed subgroup analyses according to different high risk populations, publication year, geographical area, sample size, threshold for measurement, adherence assessor and study quality, these factors may be the sources of between-study heterogeneity. However, other unmeasured factors likely affected the detected heterogeneity; unfortunately, we did not obtain sufficient information about these aspects for further analysis. Assuming homogeneity often results in a misleading analysis, since heterogeneity is very likely present but undetected, especially for very small meta-analyses\[[@pone.0146659.ref015]\]. However, we could not check that the findings stand even if we assume high levels of undetected heterogeneity. Furthermore, not enough studies for a meta-regression, especially for the multiple regression in our meta-analysis. Small meta-analyses tend not to detect existing heterogeneity and we need to be cautious when they observe apparent homogeneity \[[@pone.0146659.ref057]\]. Secondly, we did not detect publication bias using Egger's linear regression test in most of our analyses. However, these results should be interpreted with caution because the detect power is limited, particularly for moderate amounts of bias or meta-analyses based on a small number of small studies (\<10). The power to detect publication bias increased with increasing numbers of studies, and publication bias tests only relevant if there are \>10 studies otherwise underpowered to detect much and tend to lead to conclusions that are not justified. Furthermore, the risk of publication bias in older studies tends to be higher\[[@pone.0146659.ref058]\], while we did not find that older studies show larger effects. Thirdly, our results could be altered by a selection bias because different number of studies on ART adherence performed in different populations (pregnant women, children), which may impact the results. In 2003, China initiated its first PMTCT programme in eight cities which provided free HIV testing and antiretroviral (ARV) treating and/or prophylaxis through the antenatal care network. This national health service was the most widely covered and completed, with a high follow-up rate. Therefore, studies on HIV prevention and control among pregnant women were easily conducted, and a large number of individual studies related to PMTCT programmes were performed in China. Nevertheless, there was no national health service like antenatal care network to integrate HIV antiretroviral (ARV) treating and/or prophylaxis among other populations such as elderly people, which make it more difficult to conduct studies among these populations. Therefore, selection bias due to the substantially differences in the numbers of studies would be a limitation in this meta-analysis. The last, the single study conducted by Liu X et al. \[[@pone.0146659.ref026]\] used the 'blood drug concentration', one of the most accurate ways of assessing adherence, to assess adherence in this meta-analysis. However, most of the studies included used self-reported method that may introduce information bias or recall bias, which may result in overestimation of the levels of ART adherence.

Conclusion {#sec019}
==========

In conclusion, our meta-analysis found remarkable variations in adherence rate between different high risk populations, with lower adherence in HTG, FCPD and IDU, and high levels of adherence in elderly patients, children, MSM, and pregnant women. ART adherence in some high-risk population, especially in HTG, was significantly below the recommended level for maintaining virologic suppression. It is crucial to develop comprehensive intervention strategies to promote ART adherence in these high-risk populations and effectively protect against the spread of the HIV/AIDS in China.
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